Search

The article present a study revealing that a history of military service is associated with an increased risk for amyloid plaque and an increased risk for elevated tau tangle levels, underscoring the need for amyloid screening among veterans. It discusses the study, which included 597 male decedents, employed public data tracing for military history and brain pathology evaluation; and highlighting the urgency for targeted Alzheimer's disease therapies in the veteran population.

The article focuses on a large study of an experimental Alzheimer's drug, donanemab, which suggests that early treatment in the disease's mild stages offers a better chance of slowing cognitive decline.

The article focuses on a research finding that discovered a mutation in a specific gene that protected a man from developing Alzheimer's disease until a much later age. Topics include the potential for this finding to lead to new therapeutic approaches for Alzheimer's, the protein Reelin's role in preventing the formation of characteristic Alzheimer's structures, and the need for further research and combined treatments to explore this pathway.

The article focuses on the superiority of donanemab over aducanumab in treating early symptomatic Alzheimer's disease. Topics include the greater amyloid clearance and plaque reduction achieved by donanemab compared to aducanumab; the faster titration of donanemab without increased side effects; and the need for further research on the long-term effects and timing of anti-amyloid therapies for Alzheimer's treatment.

The article discusses pharmaceutical Biogen Idec's development of the Alzheimer's drug aducanumab (BIIB037), highlighting research that found that the drug slowed the decline in mental function during a clinical trial. Topics addressed include stock market reaction to the research results, the drug's reduction of amyloid plaque in the brain, and comparison's to other Alzheimer's drugs.

The article focuses on the study led by Rebecca F. Gottesman which shows the five risk factors of developing amyloid brain plaques including obesity, high blood pressure, and diabetes.

The article reports on several studies which revealed that the presence of amyloid plaques in the brain can help identify who are at risk of Alzheimer's disease and determine who has it, highlighting the views of physician Samuel Gandy on the issue.